Clinical Trials
24 trialsNCT04541108 2026-05-22
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Active not recruiting
NCT05498792 2026-05-22
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07586904 2026-05-14
Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
Xijing Hospital
Phase EARLY_PHASE1 Recruiting
NCT05728879 2026-05-01
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Northwestern University
Phase EARLY_PHASE1 Not yet recruiting
NCT07389525 2026-04-24
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Indiana University
Phase EARLY_PHASE1 Not yet recruiting
NCT06216938 2026-04-13
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
University of Pittsburgh
Phase EARLY_PHASE1 Recruiting
NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT07286318 2026-04-02
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
University of Pittsburgh
Phase EARLY_PHASE1 Not yet recruiting
NCT05651828 2026-04-01
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT04480645 2026-03-24
CivaDerm(TM) Surface Therapy Pilot Study
CivaTech Oncology
Phase EARLY_PHASE1 Completed
NCT05702398 2026-03-20
Pilot Trial of Supplemental Vitamin A and Nicotinamide
Rhode Island Hospital
Phase EARLY_PHASE1 Recruiting
NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT06305962 2026-02-19
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Phase EARLY_PHASE1 Recruiting
NCT07144384 2026-02-13
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05098184 2025-12-11
A Study of GC101 TIL in Advanced Melanoma (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT06472661 2025-11-20
Mel 70
University of Virginia
Phase EARLY_PHASE1 Recruiting
NCT07213882 2025-10-09
CITY
Assistance Publique - Hôpitaux de Paris
Phase EARLY_PHASE1 Not yet recruiting
NCT06664151 2025-10-02
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT05279027 2025-09-19
Zr89 + PET Companion Trial
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed